MapLight Therapeutics, Inc. (MPLT)
MPLTNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$7.44
+0.1600 (+2.20%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $481.92m
- P/E
- –
- EPS, last 4 quarters
- $-42.31
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.06 to $40.43
- Average volume
- 440.0k
- Previous close
- $7.28
Analysts
6 coveringBuy3 buy, 3 hold, 0 sell
Targets a year out average $26.80, +260.2% from here
Earnings
next estimate $-1.22Next report Dec 3, 2026
Sep 2025
-1898.9%
Dec 2025
-135.2%
Mar 2026
-47.3%
Jun 2026
+5.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$31.50m | -$83.38m | -$64.50m | -$63.55m |
| Net income | -$29.42m | -$79.55m | -$60.67m | -$60.19m |
News
8 latest- Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)Zacks · Oct 16, 2026
- Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround Zacks · Oct 14, 2026
- MapLight Raises $150 M PIPE To Fund CNS Pipeline RTTNews · Aug 13, 2026
- Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals RTTNews · Jul 31, 2026
- Wednesday 7/29 Insider Buying Report: CVBF, MPLT BNK Invest · Jul 29, 2026
- Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend? RTTNews · Jul 28, 2026
- Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical TensionsBarchart · Jul 28, 2026
- Stocks Rally as Middle East Tensions EaseBarchart · Jul 27, 2026
The company
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company's discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- maplightrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.